Avid Bioservices Inc (CDMO)

[jbainseky]

Funny CP how you just make stuff up. PPHM's own website says:

Second-line NSCLC: Final results from our Phase II trial, reported in June 2013, showed an improvement in median overall survival (OS) of 11.7 months in the 3 mg/kg bavituximab plus docetaxel arm compared to 7.3 months in the combined control arm (docetaxel plus 1 mg/kg bavituximab or placebo) with a persistent separation in the Kaplan Meier survival curves (HR=0.662). In addition, overall survival subgroup analyses of key patient characteristics favored the bavituximab 3 mg/kg arm, including age, gender, ECOG status, ethnicity and prior treatment. The results also indicated that the 3 mg/kg bavituximab plus docetaxel combination was well-tolerated with no significant differences in adverse events between the trial arms. Investors are reminded not to rely on clinical data that the company disclosed on or before September 7, 2012 regarding this trial.

So NO, the MOS wasn't that high, and you do think PPHM expected the BAVI phase 3 results to be better than the phase 2. Case closed.

FFTT

JBAIN